|Table of Contents|

Expression and clinical significance of large tumor suppressor kinase 2 in non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 02
Page:
258-262
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of large tumor suppressor kinase 2 in non-small cell lung cancer
Author(s):
WANG Hongjun1; JIA Jinguang1; ZHU Wanling1; WEI Ran1; YAO Feifei1; HE Wei2
1.Zhengzhou People’s Hospital,Henan Zhengzhou 450000,China;2.The First Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450000,China.
Keywords:
non-small cell lung cancer; large tumor suppressor kinase 2; proliferation; invasion
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2021.02.016
Abstract:
Objective:To detect the expression of large tumor suppressor kinase 2 (LATS2) in non-small cell lung cancer (NSCLC) tissues and cells,and its effect on the proliferation,invasion and clinical characteristics of NSCLC cells.Methods:A total of 260 patients with NSCLC who underwent surgical treatment in our hospital from June 2017 to June 2019 were collected,and the expression level of LATS2 in NSCLC tumor tissues and adjacent tissues was detected by immunohistochemical experiments.Chi-square test was used to analyze the correlation between LATS2 expression and clinical characteristics of patients.qRT-PCR was used to detect the relative expression level of LATS2 mRNA in NSCLC tumor tissues and adjacent tissues.The transfection experiment transfected the LATS2 plasmid into A549 cells.the MTT assay was used to detect the effect of LATS2 on the proliferation of A549 cells.Transwell assay was used to detect the effect of LATS2 on A549 cell invasion.Results:The expression level of LATS2 in tumor tissues was lower than adjacent tissues.The high expression rate of LATS2 was 72.3%(188/260) and the low expression rate was 27.7%(72/260).There was no statistical difference in gender,tumor type,pleural invasion,vascular invasion,lymphatic invasion,and T stage in patients with high expression and low expression in the LATS2 group.There were differences in age,tumor diameter,lymphatic metastasis and pathological grade(P＜0.05).The relative expression level of LATS2 mRNA in NSCLC tissues and cells was significantly lower than that of HPAEpiC in adjacent tissues and human normal lung epithelial cells.LATS2 plasmid was transfected into A549 cells to increase its expression level.The OD value and the number of invaded cells in the LATS2 high expression group were significantly reduced.Conclusion:LATS2 is related to the patient’s age,tumor diameter,lymph node metastasis and pathological grade.The increased expression level of LATS2 can significantly inhibit the proliferation and invasion of NSCLC cells and may become a new target for the treatment of NSCLC.

References:

［1］ NAKAMURA H,SAJI H.Worldwide trend of increasing primary adenocarcinoma of the lung［J］.Surg Today,2014,44:1004-1012.
［2］ SIEGEL RL,MILLER KD.Cancer statistics,2020［J］.CA Cancer J Clin,2020,70(1):7-30.
［3］ AYLON Y,GERSHONI A,ROTKOPF R,et al.The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation［J］.Genes Dev,2016,30(7):786-797.
［4］ ZHAO B,GUAN KL.Hippo pathway key to ploidy checkpoint［J］.Cell,2014,158(4):695-696.
［5］ ST JOHN MA,TAO W,Fei X,et al.Mice deficient of Lats1 develop soft-tissue sarcomas,ovarian tumours and pituitary dysfunction［J］.Nat Genet,1999,21:182-186.
［6］ FURTH N,PATERAS IS,ROTKOPF R,et al.LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state［J］.Life Sci Alliance,2018,1:e201800171.
［7］ KIM E,AHN B,OH H,et al.High Yes-associated protein 1 with concomitant negative LATS1/2 expression is associated with poor prognosis of advanced gastric cancer［J］.Pathology,2019,51:261-267.
［8］ YU J,HONG JF,KANG J,et al.Promotion of LncRNA HOXA11-AS on the proliferation of hepatocellular carcinoma by regulating the expression of LATS1［J］.Eur Rev Med Pharmacol Sci,2017,21(15):3402-3411.
［9］ LIU Y,LU J,ZHANG Z,et al.Amlexanox,a selective inhibitor of IKBKE,generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines［J］.Cell Death Dis 2017,8(8):e3022.
［10］ JIANG Z,LI X,HU J,et al.Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma［J］.Neurosci Res,2006,56(4):450-458.
［11］ SHI Y,GENG D,ZHANG Y,et al.LATS2 inhibits malignant behaviors of glioma cells via inactivating YAP［J］.J Mol Neurosci,2019,68(1):38-48.
［12］ LI Y,Pei J,XIA H,et al.Lats2,a putative tumor suppressor,inhibits G1/S transition［J］.Oncogene,2003,22:4398-4405.
［13］ IKEDA S.Regulation of myocardial cell growth and death by the Hippo pathway［J］.Circ J,2016,80:1511-1519.
［14］ FURTH N.The LATS1 and LATS2 tumor suppressors:Beyond the Hippo pathway［J］.Cell Death Differ,2017,24:1488-1501.
［15］ XU B,SUN D,WANG Z,et al.Expression of LATS family proteins in ovarian tumors and its significance［J］.Hum Pathol,2015,46:858-867.
［16］ YAO F,LIU H,LI Z,et al.Down-regulation of LATS2 in nonsmall cell lung cancer promoted the growth and motility of cancer cells［J］.Tumour Biol,2015,36:2049-2057.
［17］ SI-HYOHG JANG,MEE-HYE OH,HYUN DEUK CHO,et al.Low LATS2 expression is associated with poorprognos is in non-small cell lung carcinoma［J］.Pol J Pathol,2019,70(3):189-197.
［18］ FURTH N,BOSSEL BEN-MOSHE N,POZNIAK Y,et al.Down-regulationof LATS kinases alters p53 to promote cell migration［J］.Genes Dev,2015,29:2325-2330.
［19］ TIAN Y,LV W,LU C,et al.LATS2 promotes cardiomyocyte H9C2 cells apoptosis via the Prx3-Mfn2-mitophagy pathways［J］.J Recept Signal Transduct Res,2019,39:470-478.

Memo

Memo:
河南省医学科技攻关计划项目(编号:201303021)
Last Update: 1900-01-01